A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees.
about
Viral and cellular determinants involved in hepadnaviral entryGenetic variation of occult hepatitis B virus infectionHepatologyElucidation of the early infection machinery of hepatitis B virus by using bio-nanocapsuleAnalysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus.A mimotope of pre-S2 region of surface antigen of viral hepatitis B screened by phage display.Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitopeExpression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella.Phage display creates innovative applications to combat hepatitis B virusDNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen.Immunogenicity of peptide fusions to hepatitis B virus core antigen.Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopesMale-specific hepatitis B virus large surface protein variant W4P potentiates tumorigenicity and induces gender disparityValidation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection.Epitope mapping of neutralizing monoclonal antibodies against duck hepatitis B virus.Hepatitis B virus preS1 deletion is related to viral replication increase and disease progressionThe chimpanzee model for hepatitis B virus infection.Primary and secondary prevention of liver cancer caused by HBV.Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination.Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virusThe preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.Fibronectin of human liver sinusoids binds hepatitis B virus: identification by an anti-idiotypic antibody bearing the internal image of the pre-S2 domainRemoving N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine.Hepatitis B virus surface antigen binds to apolipoprotein H.Hepatitis B virus (HBV) binding factor in human serum: candidate for a soluble form of hepatocyte HBV receptorThe position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S proteinHuman liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 regionMale-specific W4P/R mutation in the pre-S1 region of hepatitis B virus, increasing the risk of progression of liver diseases in chronic patients.DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines.Plant-based vaccines against human hepatitis B virus.Mother-to-child transmission of HBV: review of current clinical management and prevention strategies.Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.Enhanced humanization and affinity maturation of neutralizing anti-hepatitis B virus preS1 antibody based on antigen-antibody complex structure.Molecular analysis of Hepatitis B virus sub-genotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura.Production of infectious hepatitis delta virus in vitro and neutralization with antibodies directed against hepatitis B virus pre-S antigens.Expression of hepatitis B virus middle and large surface antigen genes in Saccharomyces cerevisiae.Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.
P2860
Q24563902-70975414-22EF-43F8-A1CC-869808E843FFQ26751031-5DF8B3ED-633B-4A91-B7CA-FEC4D8005D3FQ27486176-32948CBA-F89D-441A-BA3A-0E158E053871Q28070320-F6ADC2CB-5A11-4566-AB32-7787D446DBDFQ30671216-27305FD9-2800-491C-B58C-5C9241FF5DF6Q31026231-3877B5B7-5B62-4110-B290-4010AA6D74D8Q33557944-08E59740-CC50-4B56-AB9D-AFCF7E02D70CQ33864236-AE2764FB-BBFA-4192-954E-DC6A3EE9AAADQ34137308-307A765C-A2A7-4B78-B8F1-6399D95B2EBFQ34209003-43EAE022-B3F1-4923-BFE0-6451AB4DCFF2Q34225571-B385B61E-69DB-4F10-B0FA-85AAA3E6378EQ34297568-7AFCFD68-24DE-43D9-97C0-F6A29B3A76BAQ34321397-830FC058-3EB0-49ED-B25A-91CC0188D77BQ35078603-5BF13665-7463-4FA6-A489-95997C8B75F6Q35097179-E2BF6B24-594D-4FE3-BD7F-9D31964EF902Q35141530-5BF8EFDE-A51A-4A82-8BCE-2CDE21196231Q35534117-2DB88FA1-41AB-4312-BC15-52D92178B8EFQ35664171-B59D5247-A22D-4D53-9327-0593EC32D649Q35777982-5371DEC6-EA3B-4574-8998-6E84B8624FF1Q35779035-A374DB35-5D9F-4C48-BF4D-466578D82401Q35802832-7E8D1DFD-3EFB-44D0-AFF4-F81C33683430Q35816248-28BE2F3A-BCDA-4983-9EC0-44F9E61F7482Q35831642-B0E8FECA-6999-40AE-8D45-555C37717C5EQ36109563-7ABB6B5B-F928-47F5-9BBC-8C4FE22EFA3DQ36632110-ED393ADE-712F-46B6-9B66-B300606EB8EDQ36650363-BCAA1FB9-4281-444E-8899-EAC05BD74AB0Q36655876-0498E2B3-643C-49E9-9360-7B76B6C1442FQ36802452-EF12015B-959E-473E-8D3F-B7C624D5118FQ36827256-D609EE02-581A-4592-8F56-0E74D070B615Q37336320-506B03FE-07AF-46BA-A2D0-C596EE33217DQ37495259-4C0B5B8E-EC37-4CB0-A51A-E2BED5B648B7Q37776722-2E4D4874-4295-47F6-81E8-810B8C9643A2Q38222498-74590E72-D204-46D7-8239-2A67CCCE81E5Q38293584-9F15C28B-1D12-4583-846E-7435C26736BEQ38306933-B459BEC2-5363-44E9-98CF-1363B55DF9D7Q38931731-E3D2BC14-BD7A-4DFB-94C9-F7F755B4850AQ38988884-CE613E67-095A-4386-A3E1-2CBB47F0C74CQ40064217-DC114194-AA15-45A8-9D54-CDE0DE343852Q40141149-3ECDBC69-3D7E-4146-8AAF-C8B5926394B6Q40159003-0B89865F-0256-4A00-9BBE-88E259CEDFE1
P2860
A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1986
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A synthetic peptide vaccine involving the product of the pre-S
@nl
A synthetic peptide vaccine in ...... ctive efficacy in chimpanzees.
@en
type
label
A synthetic peptide vaccine involving the product of the pre-S
@nl
A synthetic peptide vaccine in ...... ctive efficacy in chimpanzees.
@en
prefLabel
A synthetic peptide vaccine involving the product of the pre-S
@nl
A synthetic peptide vaccine in ...... ctive efficacy in chimpanzees.
@en
P2093
P2860
P356
P1476
A synthetic peptide vaccine in ...... ctive efficacy in chimpanzees.
@en
P2093
Kitajima K
Miyakawa Y
Nakamura T
P2860
P304
P356
10.1073/PNAS.83.23.9174
P407
P577
1986-12-01T00:00:00Z